NCT05991388 2026-02-20
Glo-BNHL
University of Birmingham
Phase 2/3 Recruiting
Clinical Trials
9 trialsNCT05016947 2026-01-29
Venetoclax Plus Inotuzumab for B-ALL
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT03114865 2025-05-22
A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Active not recruiting
NCT05476770 2024-12-06
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1 Recruiting
NCT02741388 2021-12-07
SELINDA
The Lymphoma Academic Research Organisation
Phase 1 Completed
NCT00290498 2020-06-02
Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01722305 2019-07-22
Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular Lymphoma
Mayo Clinic
Phase 1 Completed
NCT00413959 2018-09-19
VRCD
Oncology Specialists, S.C.
Phase 2 Terminated
NCT02983097 2018-01-19
R²-DHAP
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Phase 1/2 Terminated